Synthesis and Biological Activity of Diastereomeric and Geometric Analogs of Calcipotriol, PRI-2202 and PRI-2205, Against Human HL-60 Leukemia and MCF-7 Breast Cancer Cells

Cancers

Volumn 5, Issue 4, 2013, Pages 1355-1378

  Milczarek, Magdalena ^a   Chodyński, Michał ^b   Filip Psurska, Beata ^a   Martowicz, Agnieszka ^a   Krupa, Małgorzata ^b   Krajewski, Krzysztof ^b   Kutner, Andrzej ^b   Wietrzyk, Joanna ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Antiproliferative activity; Calcipotriol; Cancer; Combined treatment; Convergent synthesis; VDR; Vitamin D analogs

Indexed keywords

EID: 84906088077     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5041355     Document Type: Article

References (45)

1. Krishnan, A.V.; Trump, D.L.; Johnson, C.S.; Feldman, D. The role of vitamin D in cancer prevention and treatment. Rheum. Dis. Clin. North Am. 2012, 38, 161–178.
2. Mocellin, S. Vitamin D and cancer: Deciphering the truth. Biochim. Biophys. Acta 2011, 1816, 172–178.
3. Lopes, N.; Paredes, J.; Costa, J.L.; Ylstra, B.; Schmitt, F. Vitamin D and the mammary gland: A REVIEW on its role in normal development and breast cancer. Breast Cancer Res. 2012, 14, doi:10.1186/bcr3178.
4. Luna, N.D.; Diaz-Manera, J.; Paradas, C.; Iturriaga, C.; Rojas-Garcia, R.; Araque, J.; Genebriera, M.; Gich, I.; Illa, I.; Gallardo, E. 1alpha,25(OH)(2)-Vitamin D3 increases dysferlin expression in vitro and in a human clinical trial. Mol. Ther. 2012, 20, 1988–1997.
5. Haussler, M.R.; Haussler, C.A.; Jurutka, P.W.; Thompson, P.D.; Hsieh, J.C.; Remus, L.S.; Selznick, S.H.; Whitfield, G.K. The vitamin D hormone and its nuclear receptor: Molecular actions and disease states. J. Endocrinol. 1997, 154, S57–S73.
6. Ross, T.K.; Darwish, H.M.; Moss, V.E.; DeLuca, H.F. Vitamin D-influenced gene expression via a ligand-independent, receptor-DNA complex intermediate. Proc. Natl. Acad. Sci. USA 1993, 15, 9257–9260.
7. Sánchez-Martínez, R.; Zambrano, A.; Castillo, A.I.; Aranda, A. Vitamin D-dependent recruitment of corepressors to vitamin D/retinoid X receptor heterodimers. Mol. Cell Biol. 2008, 28, 3817–329.
8. Costa, J.L.; Eijk, P.P.; van de Wiel, M.A.; Ten, B.D.; Schmitt, F.; Narvaez, C.J.; Welsh, J.; Ylstra, B. Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down. BMC Genomics 2009, 10, doi:10.1186/1471-2164-10-499.
9. Nemere, I.; Ray, R.; McManus, W. Immunochemical studies on the putative plasmalemmal receptor for 1, 25(OH)(2)D(3). I. Chick intestine. Am. J. Physiol. Endocrinol. Metab. 2000, 278, E1104–E1114.
10. Wu, W.; Beilhartz, G.; Roy, Y.; Richard, C.L.; Curtin, M.; Brown, L.; Cadieux, D.; Coppolino, M.; Farach-Carson, M.C.; Nemere, I.; et al. Nuclear translocation of the 1,25D3-MARRS (membrane associated rapid response to steroids) receptor protein and NFkappaB in differentiating NB4 leukemia cells. Exp. Cell Res. 2010, 316, 1101–1108.
11. Chen, J.; Doroudi, M.; Cheung, J.; Grozier, A.L.; Schwartz, Z.; Boyan, B.D. Plasma membrane Pdia3 and VDR interact to elicit rapid responses to 1α,25(OH)2D3. Cell. Signal. 2013, 27, 2362–2373.
12. Wietrzyk, J.; Pelczynska, M.; Madej, J.; Dzimira, S.; Kusnierczyk, H.; Kutner, A.; Szelejewski, W.; Opolski, A. Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids 2004, 69, 629–635.
13. Chodynski, M.; Wietrzyk, J.; Marcinkowska, E.; Opolski, A.; Szelejewski, W.; Kutner, A. Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D(2). (24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners. Steroids 2002, 67, 789–798.
14. Opolski, A.; Wietrzyk, J.; Siwinska, A.; Marcinkowska, E.; Chrobak, A.; Radzikowski, C.; Kutner, A. Biological activity in vitro of side-chain modified analogues of calcitriol. Curr. Pharm. Des. 2000, 6, 755–765.
15. Wietrzyk, J.; Milczarek, M.; Kutner, A. The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics. Oncol. Res. 2007, 16, 517–525.
16. Wietrzyk, J.; Nevozhay, D.; Milczarek, M.; Filip, B.; Kutner, A. Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother. Pharmacol. 2008, 62, 787–797.
17. Filip, B.; Milczarek, M.; Wietrzyk, J.; Chodynski, M.; Kutner, A. Antitumor properties of (5E,7E) analogs of vitamin D3. J. Steroid Biochem. Mol. Biol. 2010, 121, 399–402.
18. Wietrzyk, J.; Chodynski, M.; Fitak, H.; Wojdat, E.; Kutner, A.; Opolski, A. Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs 2007, 18, 447–457.
19. Hisatake, J.; Kubota, T.; Hisatake, Y.; Uskokovic, M.; Tomoyasu, S.; Koeffler, H.P. 5,6-trans-16-ene-vitamin D3: A new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res. 1999, 59, 4023–4029.
20. Wecksler, W.R.; Okamura, W.H.; Norman, A.W. Studies on the mode of action of vitamin D—XIV. Quantitative assessment of the structural requirements for the interaction of 1 alpha, 25-dihydroxyvitamin D3 with its chick intestinal mucosa receptor system. J. Steroid Biochem. 1978, 9, 929–937.
21. Milczarek, M.; Rosinska, S.; Psurski, M.; Maciejewska, M.; Kutner, A.; Wietrzyk, J. Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res. 2013, 33, 433–444.
22. Kutner, A. Convergent synthesis of vitamin D analogs (Konwergentna synteza analogów witamin D). Przemysł Chemiczny 2006, 85, 322–329.
23. Kutner, A.; Chodynski, M.; Fitak, H.; Krupa, M.; Wietrzyk, J.; Szelejewski, W. The use of vitamin D analogs in the treatment of antineoplastic diseases. Pol. Pat. Appl. P-378586, 3 January 2006.
24. Chodynski, M.; Krupa, M.; Fitak, H.; Winiarski, J.; Ryznar, T.; Górecki, B.; Szelejewski, W.; Kutner, A. Process and intermediates to prepare the sulphonyl derivatives of cholecalciferol. Patent WO 2005/110979 A2, 24 November 2005.
25. Hilpert, H.; Wirz, B. Novel versatile approach to an enantiopure 19-nor, des-C,D vitamin D3 derivative. Tetrahedron 2001, 57, 681–694.
26. Blakemore, P.R.; Kocieński, P.J.; Morley, A.; Muir, K. A synthesis of herboxidiene. J. Chem. Soc. Perkin Trans. I 1999, 1, 955–968.
27. De Luca, H.F.; Schnoes, H.K.; Hamer, D.E.; Paaren, D.E. Process for preparing 1-hydroxylated vitamin D compounds from 5,6-trans-vitamin D compounds. Patent US4265822 A, 5 May1981.
28. Ravid, A.; Rocker, D.; Machlenkin, A.; Rotem, C.; Hochman, A.; Kessler-Icekson, G.; Liberman, U.A.; Koren, R. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. 1999, 59, 862–867.
29. Wang, X.; Studzinski, G.P. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J. Cell Biochem. 2001, 80, 471–482.
30. Welsh, J.; Wietzke, J.A.; Zinser, G.M.; Smyczek, S.; Romu, S.; Tribble, E.; Welsh, J.C.; Byrne, B.; Narvaez, C.J. Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J. Steroid Biochem. Mol. Biol. 2002, 83, 85–92.
31. Wietrzyk, J.; Nevozhay, D.; Filip, B.; Milczarek, M.; Kutner, A. The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res. 2007, 27, 3387–3398.
32. Trotter, J. WinMDI Version 2.9. The Scripps Research Institute: La Jolla, CA, USA, 2000.
33. Chrobak, A.; Radzikowski, C.; Opolski, A. Side-chain-modified analogs of calcitriol cause resistance of human HL-60 promyelocytic leukemia cells to drug-induced apoptosis. Steroids 2005, 70, 19–27.
34. Del Bino, G.; Li, X.; Traganos, F.; Darzynkiewicz, Z. Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs. Leukemia 1994, 8, 281–288.
35. Kleuser, B.; Cuvillier, O.; Spiegel, S. 1Alpha,25-dihydroxyvitamin D3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase. Cancer Res. 1998, 58, 1817–1824.
36. Wang, X.; Studzinski, G.P. Antiapoptotic action of 1,25-dihydroxyvitamin D3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome C. Exp. Cell Res. 1997, 235, 210–217.
37. Siwinska, A.; Opolski, A.; Chrobak, A.; Wietrzyk, J.; Wojdat, E.; Kutner, A.; Szelejewski, W.; Radzikowski, C. Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res. 2001, 21, 1925–1929.
38. Switalska, M.; Nasulewicz-Goldeman, A.; Opolska, A.; Maciejewska, M.; Kutner, A.; Wietrzyk, J. The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells. Anticancer Drugs 2012, 23, 70–80.
39. Milczarek, M.; Psurski, M.; Kutner, A.; Wietrzyk, J. Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer 2013, 13, doi:10.1186/1471-2407-13-294.
40. Escaleira, M.T.; Sonohara, S.; Brentani, M.M. Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells. J. Steroid Biochem. Mol. Biol. 1993, 45, 257–263.
41. Abe-Hashimoto, J.; Kikuchi, T.; Matsumoto, T.; Nishii, Y.; Ogata, E.; Ikeda, K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res. 1993, 53, 2534–2537.
42. Riggins, R.B.; Schrecengost, R.S.; Guerrero, M.S.; Bouton, A.H. Pathways to tamoxifen resistance. Cancer Lett. 2007, 256, 1–24.
43. Chodynski, M.; Fitak, H.; Kutner, A.; Leszczynska, K.; Szelejewski, W. Process for the preparation of calcipotriol. Patent WO 2009008754 A2, 15 January 2009.
44. Kutner, A.; Chodynski, M.; Szelejewski, W.; Odrzywolska, M.; Fitak, H. Method of preparation of cholecalciferol derivatives and new intermediate compounds. Patent WO 1999036400 A1, 29 December 1998.
45. 3. J. Pharm. Sci. 2013, 102, doi 10.1002/ips.23701.